Every earnings call for ZIMLAB — management tone, guidance, KPIs and promise tracking, quarter by quarter.
ZIMLAB · 5 transcripts · Healthcare · latest Q4 FY26Zim Laboratories Limited has 5 earnings calls on record here, a Healthcare company, most recently Q4 FY26. Each quarter is scored on revenue, margins, guidance delivery and the questions management left unanswered — so the gap between what was promised and what was delivered is easy to read.
EBITDA ₹13 cr; EBITDA Margin 12.7%; PAT ₹4 cr. Q4 FY26 Total Operating Income at INR 105.3 crores.
Read full transcript & analysisEBITDA (Q3 FY26) 145 million; EBITDA Margin (Q3 FY26) 13.4%. Operating income of INR 1,087 million in Q3 FY26, showing sequential and YoY improvement.
Read full transcript & analysisEBITDA 78 million; EBITDA Margin 8.8%; PAT -4 million. Total operating income at INR887 million, up 23.6% QoQ.
Read full transcript & analysisEBITDA 57 million (−37% YoY); EBITDA Margin 7.9%; PAT -19 million. Total operating income declined 12.3% YoY to INR718 million.
Read full transcript & analysisEBITDA ₹16 cr (−5% YoY); EBITDA Margin 15.0%; PAT ₹5 cr (−40% YoY). FY25 Total Operating Income grew 3.2% YoY to INR 379 crores.
Read full transcript & analysis